转变的范式和严重血友病中出现的担忧 治疗一种治疗方法
Rubhan Chandran1,2, Eusni R Mohd Tohit1, Johnson Stanslas3
1Department of Pathology, Haematology Unit, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.
Seminars in thrombosis and hemostasis
|January 15, 2024
概括
血友病A的管理已经进步,新的第八因子疗法和基因疗法提供了更好的结果. 然而,新出现的并发症和高成本对患者的获取和护理构成了持续的挑战.
科学领域:
- 血液学 血液学 血液学
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病A的管理已经发生了显著的进化,从感染的担忧转向改善预防的遵守性和提高因子VIII (FVIII) 缩剂的疗效.
- 先进的查和病毒失活在很大程度上减轻了与FVIII缩物相关的感染风险.
研究的目的:
- 审查血友病A治疗的最新进展,包括新型FVIII缩剂,双特异性抗体和基因疗法.
- 讨论新出现的非传染性并发症和在获得新血友病A疗法的挑战.
主要方法:
- 关于重组FVIII (rFVIII) 修饰的最近生物工程研究的审查 (例如,B域删除,PEGylated,Fc-fused).
- 分析目前可用的和正在研究的治疗方法,如埃米齐祖马布,菲图西兰和基因疗法.
- 讨论非传染性并发症 (抑制剂,过敏反应,血栓形成) 和与成本相关的接入问题.
主要成果:
- 开发延长半衰期的rFVIII缩剂和新药,如埃米齐祖马布.
- 基因疗法的批准标志着朝着治疗血友病A.A.的潜在疗法迈出的重要一步.
- 非传染性并发症和高治疗成本是关键的挑战.
结论:
- 现代血友病A治疗提供了定制的,有效的选择,包括基因疗法.
- 谨慎管理非传染性并发症并解决成本障碍对于公平的患者护理至关重要.
- 目前正在进行的研究旨在进一步提高治疗的有效性和可访问性.
更多相关视频
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
01:24Disorders of Hemostasis
918
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
918
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:05Introduction to Hemostasis
7.8K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.8K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
02:45Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K